- To widen market potential, pharma companies must roll out long-lasting therapies that delay or prevent disease progression

BUENOS AIRES, Argentina, Feb. 18, 2014 /PRNewswire/ -- The Latin American diabetes therapeutics market will experience major changes within the next three years due to the launch of innovative drugs that include three long-acting insulins and four non-insulin treatments. Nevertheless, pharmaceutical companies should continue their research to develop treatments that can restore beta-cell function and thereby postpone or prevent disease progression – areas that even newer therapies do not address.

New analysis from Frost & Sullivan (http://www.lifesciences.frost.com), Trends, Opportunities, and Challenges for the Latin American Diabetes Therapeutics Market, expects the diabetes therapeutics market to grow due to the rising prevalence of diabetes in the region. Improved awareness among patients on the importance of early diagnosis and treatment of diabetes will ensure steady market growth in the next five years. The research covers non-insulin and insulin therapeutics.

Currently, type 2 diabetic patients with metabolic syndrome need to separately administer drugs for each diabetes, arterial hypertension, and hyperlipidemia. As a result, pharmaceutical companies are focusing on drugs that increase the administration period while controling elevated glucose levels and normalizing the lipid profile.

"Pharmaceutical companies are looking to introduce into the Latin American market fixed-dose, single-tablet products that will offer a new treatment panorama for type 2 diabetes patients with metabolic syndrome disorder by reducing the daily intake of pills," elaborated Frost & Sullivan Healthcare Industry Analyst Lucila Rocca.

However, some Latin American governments are promoting the development of insulin by local companies at a cheaper price since the public system pays for the bulk of diabetes treatments. Thus,  generics become an interesting option due to their low pricing. The products that are being developed and purchased are mostly human or animal insulins, which is a threat for multinationals since they generate maximum revenue from analog insulins.

"In this scenario, pharmaceutical companies need to formulate an appropriate pricing strategy and educate society on the therapeutic and administration benefits of analog insulins over human or animal products to boost the sale volumes of analog insulins in the public segment," advised Rocca. "Pharmaceutical companies should also offer prophylatic therapies based on genetic disposition since the population with prediabetes in Latin America is estimated to be approximately three times the size of the diabetes population."

If you are interested in more information on this research, please send an e-mail to Francesca Valente, Corporate Communications, at francesca.valente@frost.com, with your full name, company name, job title, telephone number, company e-mail address, company website, city, state and country.

Trends, Opportunities, and Challenges for the Latin American Diabetes Therapeutics Market is part of the Life Sciences Growth Partnership Service program. Frost & Sullivan's related research services include: China's 2013 Life Sciences Industry Outlook and Regulatory Review, Competitive Analysis of the Global Opioid Therapeutics Market, and A Product and Pipeline Analysis of the Latin American HIV, Chagas, Dengue, and Influenza H1N1 Therapeutics Markets. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

• The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
• The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion 

Join Us:           Join our community 

Subscribe:       Newsletter on "the next big thing" 

Register:         Gain access to visionary innovation

Trends, Opportunities, and Challenges for the Latin American Diabetes Therapeutics Market
ND63-52

Contact:
Francesca Valente
Corporate Communications – Latin America
P: +54-11-4777-5300
F: +54-11-4777-5300
E: francesca.valente@frost.com 
http://www.frost.com

SOURCE Frost & Sullivan